Galderma
Galderma is a Swiss dermatology company, listed in 2024, whose cancer-related trials concern photodynamic therapy for actinic keratosis and basal cell carcinoma.
Overview
Galderma, based in Zug and listed on the SIX Swiss Exchange since 2024, is a dermatology company spanning prescription medicines, aesthetics and consumer skin care. Its cancer-related registry trials mostly concern methyl aminolevulinate photodynamic therapy (Metvix) for actinic keratosis and superficial basal cell carcinoma. OnCo records it so that those phase 3 trials resolve to a sponsor page.
Similar pages
not linked directly; found by shared links- CompanyAlmirall
Shares Cutaneous squamous cell carcinoma and the tag ctgov-sponsor.
- CompanyLEO Pharma
Shares Cutaneous squamous cell carcinoma and the tag ctgov-sponsor.
- CompanyRakuten Medical
Shares Cutaneous squamous cell carcinoma and the tag ctgov-sponsor.
- CompanyPhilogen S.p.A.
Shares Basal cell carcinoma and the tag ctgov-sponsor.
- TechnologyBlack salve and other escharotic pastes
Shares Basal cell carcinoma, Cutaneous squamous cell carcinoma.
- Key paperEsteva 2017: a deep neural network classifies skin cancer at dermatologist level
Shares Basal cell carcinoma, Cutaneous squamous cell carcinoma.
- TreatmentImiquimod
Shares Basal cell carcinoma, Cutaneous squamous cell carcinoma.
- TechnologySkin cancer screening (visual skin examination)
Shares Basal cell carcinoma, Cutaneous squamous cell carcinoma.